Citius Pharmaceuticals Inc vs Elastic NV — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while Elastic NV trades at $76.12 (market cap $7.94B). The key difference: Elastic NV is far larger — about 396.8× Citius Pharmaceuticals Inc's market cap, and Elastic NV is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | ESTC | |
|---|---|---|
Market Cap | $20.01M | $7.94B |
Sector | Health | Technology |
52-Week High | $1.82 | $94.47 |
52-Week Low | $0.48 | $43.30 |
Enterprise Value | $16.23M | $7.16B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Elastic (ESTC) trades at $75.88, down 0.58% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. Recent earnings beats and a projected net profit margin of 21.14% for 2026 highlight improving fundamentals, while collaborations with OpenAI and AWS security distinctions underscore strategic growth. The stock faces headwinds from high valuation multiples and a negative net income in 2025.
The outlook remains positive given analyst consensus and product innovations, but risks include elevated P/E and EV/EBITDA ratios, potential legal scrutiny, and competitive pressures. Upside is supported by a $106 high price target, though investor caution is warranted near-term due to overbought RSI levels.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →